Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Filing for WHO Emergency Use Authorisation this month
Advances deployment of mRNA technology across vaccines and therapeutics development
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Subscribe To Our Newsletter & Stay Updated
